Literature DB >> 18381904

Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood.

Salvatore Mannuzza1, Rachel G Klein, Nhan L Truong, John L Moulton, Erica R Roizen, Kathryn H Howell, Francisco X Castellanos.   

Abstract

OBJECTIVE: Animal studies have shown that age at stimulant exposure is positively related to later drug sensitivity. The purpose of this study was to examine whether age at initiation of stimulant treatment in children with attention deficit hyperactivity disorder (ADHD) is related to the subsequent development of substance use disorders.
METHOD: The authors conducted a prospective longitudinal study of 176 methylphenidate-treated Caucasian male children (ages 6 to 12) with ADHD but without conduct disorder. The participants were followed up at late adolescence (mean age=18.4 years; retention rate=94%) and adulthood (mean age=25.3; retention rate=85%). One hundred seventy-eight comparison subjects also were included. All subjects were diagnosed by blinded clinicians. The Cox proportional hazards model included the following childhood predictor variables: age at initiation of methylphenidate treatment, total cumulative dose of methylphenidate, treatment duration, IQ, severity of hyperactivity, socioeconomic status, and lifetime parental psychopathology. Separate models tested for the following four lifetime outcomes: any substance use disorder, alcohol use disorder, non-alcohol substance use disorder, and stimulant use disorder. Other outcomes included antisocial personality, mood, and anxiety disorders.
RESULTS: There was a significant positive relationship between age at treatment initiation and non-alcohol substance use disorder. None of the predictor variables accounted for this association. Post hoc analyses showed that the development of antisocial personality disorder explained the relationship between age at first methylphenidate treatment and later substance use disorder. Even when controlling for substance use disorder, age at stimulant treatment initiation was significantly and positively related to the later development of antisocial personality disorder. Age at first methylphenidate treatment was unrelated to mood and anxiety disorders.
CONCLUSIONS: Early age at initiation of methylphenidate treatment in children with ADHD does not increase the risk for negative outcomes and may have beneficial long-term effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18381904      PMCID: PMC2967384          DOI: 10.1176/appi.ajp.2008.07091465

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  30 in total

Review 1.  Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.

Authors:  Laurence L Greenhill; Steven Pliszka; Mina K Dulcan; William Bernet; Valerie Arnold; Joseph Beitchman; R Scott Benson; Oscar Bukstein; Joan Kinlan; Jon McClellan; David Rue; Jon A Shaw; Saundra Stock
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-02       Impact factor: 8.829

2.  Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study.

Authors:  Russell A Barkley; Mariellen Fischer; Lori Smallish; Kenneth Fletcher
Journal:  Pediatrics       Date:  2003-01       Impact factor: 7.124

Review 3.  Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review.

Authors:  S H Kollins; E K MacDonald; C R Rush
Journal:  Pharmacol Biochem Behav       Date:  2001-03       Impact factor: 3.533

Review 4.  Long-term effects of stimulant medications on the brain: possible relevance to the treatment of attention deficit hyperactivity disorder.

Authors:  B Vitiello
Journal:  J Child Adolesc Psychopharmacol       Date:  2001       Impact factor: 2.576

5.  Enhanced reactivity and vulnerability to cocaine following methylphenidate treatment in adolescent rats.

Authors:  C L Brandon; M Marinelli; L K Baker; F J White
Journal:  Neuropsychopharmacology       Date:  2001-11       Impact factor: 7.853

6.  Altered responsiveness to cocaine in rats exposed to methylphenidate during development.

Authors:  Susan L Andersen; Andreas Arvanitogiannis; Andrea M Pliakas; Celeste LeBlanc; William A Carlezon
Journal:  Nat Neurosci       Date:  2002-01       Impact factor: 24.884

7.  Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study.

Authors:  Joseph Biederman; Michael C Monuteaux; Eric Mick; Thomas Spencer; Timothy E Wilens; Julie M Silva; Lindsey E Snyder; Stephen V Faraone
Journal:  Psychol Med       Date:  2006-02       Impact factor: 7.723

8.  Trends in the prescribing of psychotropic medications to preschoolers.

Authors:  J M Zito; D J Safer; S dosReis; J F Gardner; M Boles; F Lynch
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

9.  Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder.

Authors: 
Journal:  Pediatrics       Date:  2001-10       Impact factor: 7.124

10.  Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  F Xavier Castellanos; Patti P Lee; Wendy Sharp; Neal O Jeffries; Deanna K Greenstein; Liv S Clasen; Jonathan D Blumenthal; Regina S James; Christen L Ebens; James M Walter; Alex Zijdenbos; Alan C Evans; Jay N Giedd; Judith L Rapoport
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

View more
  89 in total

Review 1.  An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Authors:  Timothy E Wilens; Nicholas R Morrison; Jefferson Prince
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

2.  Attention deficit hyperactivity symptoms and risky sexual behavior in young adult women.

Authors:  G M Monawar Hosain; Abbey B Berenson; Howard Tennen; Lance O Bauer; Z Helen Wu
Journal:  J Womens Health (Larchmt)       Date:  2012-02-03       Impact factor: 2.681

3.  Preventative treatment in an animal model of ADHD: Behavioral and biochemical effects of methylphenidate and its interactions with ovarian hormones in female rats.

Authors:  Jodi L Lukkes; Nadja Freund; Britta S Thompson; Shirisha Meda; Susan L Andersen
Journal:  Eur Neuropsychopharmacol       Date:  2016-07-05       Impact factor: 4.600

4.  Stimulant ADHD medication and risk for substance abuse.

Authors:  Zheng Chang; Paul Lichtenstein; Linda Halldner; Brian D'Onofrio; Eva Serlachius; Seena Fazel; Niklas Långström; Henrik Larsson
Journal:  J Child Psychol Psychiatry       Date:  2013-10-25       Impact factor: 8.982

Review 5.  Neurobehavioral changes arising from early life dopamine signaling perturbations.

Authors:  Lorena B Areal; Randy D Blakely
Journal:  Neurochem Int       Date:  2020-04-20       Impact factor: 3.921

6.  Brain gray matter deficits at 33-year follow-up in adults with attention-deficit/hyperactivity disorder established in childhood.

Authors:  Erika Proal; Philip T Reiss; Rachel G Klein; Salvatore Mannuzza; Kristin Gotimer; Maria A Ramos-Olazagasti; Jason P Lerch; Yong He; Alex Zijdenbos; Clare Kelly; Michael P Milham; F Xavier Castellanos
Journal:  Arch Gen Psychiatry       Date:  2011-11

7.  Glutaminergic signaling in the caudate nucleus is required for behavioral sensitization to methylphenidate.

Authors:  Nicholas King; Samuel Floren; Natasha Kharas; Ming Thomas; Nachum Dafny
Journal:  Pharmacol Biochem Behav       Date:  2019-06-19       Impact factor: 3.533

8.  Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments.

Authors:  Chloe J Jordan; Roxann C Harvey; Britahny B Baskin; Linda P Dwoskin; Kathleen M Kantak
Journal:  Drug Alcohol Depend       Date:  2014-04-28       Impact factor: 4.492

9.  Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.

Authors:  Brooke S G Molina; Stephen P Hinshaw; L Eugene Arnold; James M Swanson; William E Pelham; Lily Hechtman; Betsy Hoza; Jeffery N Epstein; Timothy Wigal; Howard B Abikoff; Laurence L Greenhill; Peter S Jensen; Karen C Wells; Benedetto Vitiello; Robert D Gibbons; Andrea Howard; Patricia R Houck; Kwan Hur; Bo Lu; Sue Marcus
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-02-08       Impact factor: 8.829

Review 10.  Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.

Authors:  Marit D Moen; Susan J Keam
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.